Table 3 Characteristics of primary AML patients
| Â | Diagnose | Gender | Age (year) | FAB type | Cytogenetics | Molecular |
|---|---|---|---|---|---|---|
AML#1 | Refractory | Female | 30 | M2a | 46, XX | NARAS |
AML#2 | De novo | Female | 40 | NA | 46, XX | BCR/ABL BCORL1 KMT2C |
AML#3 | Refractory | Male | 63 | M2 | 46, XY | RUNX1 |
AML#4 | De novo | Female | 64 | M2 | 46, XX | SH2B3 |
AML#5 | Refractory | Female | 67 | M4 | 46, XX | Â |
AML#6 | Refractory | Female | 33 | M5 | 46, XX | FLT3-ITD NPM1 |
AML#7 | De novo | Female | 33 | M4 | 46, XX | WT1 MLL-AF9 |
AML#8 | Refractory | Female | 73 | M0 | 46, XX | CBFB-MYH11 WT1 |